Mubi Buys Its Way Into Theatrical

Mubi, the London-headquartered streaming service and film distributor founded in 2007, finished its 2024 financial year with specifically-transformed operations. The service’s theatrical distribution arm, which had operated as an occasional-release platform for its streaming-service acquisitions across the 2020-2023 period, released seven titles theatrically in 2024, collecting approximately $78 million in reported theatrical gross globally. The Substance, which Mubi acquired at Cannes 2024 and released theatrically in the subsequent months, accounted for approximately $69 million of that total.

The company has become, by the specific 2024 count, one of the ten most active theatrical acquirers in the independent market, alongside Neon, A24, Searchlight, Focus Features, Sony Pictures Classics, Magnolia, IFC, Bleecker Street, and Roadside Attractions. Its position has specifically shifted across a relatively short period. In 2021, the company operated at perhaps a tenth of its current theatrical scale.

The specifically-recent commercial arc

Mubi’s 2024 commercial performance was substantially driven by The Substance. Coralie Fargeat’s body-horror film, which the company acquired for approximately $12.5 million in worldwide rights excluding the United States (where Mubi later expanded its rights footprint), grossed approximately $77 million worldwide theatrically. It received five Academy Award nominations, winning one (Best Makeup and Hairstyling), and generated substantial further revenue through PVOD, streaming, and home-video windows.

The specific commercial return The Substance produced for Mubi, including its streaming-service subscriber acquisition value, is difficult to calculate from public disclosures but is consistently described in industry reporting as materially profitable. The rights acquisition cost was recovered through theatrical gross alone, with all subsequent-window revenue and streaming-subscriber-acquisition value flowing as incremental return.

What else Mubi released

The 2024 slate included Priscilla (from A24 in certain international territories), Poor Things international support, All of Us Strangers, La Chimera, Perfect Days, and The Taste of Things in certain territories. Mubi operates heavily as an international rights acquirer, licensing films for theatrical release in the UK, Germany, Italy, Spain, Netherlands, Turkey, and other markets where US-based distributors do not operate. The 2025 slate includes The Seed of the Sacred Fig, Viet and Nam, and several Sundance 2025 acquisitions across the second and third quarters.

The streaming-service economics

Mubi’s streaming service has operated since 2007 on a curated one-film-per-day release model with a rotating library of approximately 30 films. US subscription pricing is approximately $12.99 per month. Total subscriber count is not publicly disclosed but is consistently described in industry reporting as 1 to 2 million, substantially smaller than the majors. The commercial logic is that theatrical release for curated titles builds the recognition that makes subscribers loyal. Per-subscriber acquisition cost is higher than at the majors; retention rates across multi-year cohorts are higher than at most comparable services.

The 2024 funding context

Mubi raised approximately $100 million in May 2024, valuing the company at roughly $850 million, led by Sequoia Capital with Atwater Capital participation. Use of proceeds, as disclosed, was to expand theatrical acquisition budgets and fund increased in-house production. Mubi’s reported 2024 theatrical acquisition spend was approximately $35 to 45 million, up from the $15 to 20 million annual spend of the 2020-2022 period.

What Mubi is doing that the majors are not

Mubi’s distinction against the major streamers is its commitment to theatrical exclusivity for acquisitions. Where Netflix, Apple, and Amazon compress theatrical windows (often releasing awards-qualifying titles for a week or less before streaming), Mubi operates extended windows. The Substance ran theatrically in major Mubi markets for approximately eight weeks before moving to the streaming service. That extended exclusivity was a factor in the theatrical gross the film generated, and the commercial arc validated the theory that theatrical exclusivity benefits both the film and the subscriber-acquisition effect the service derives from curated theatrical acquisition.

The risk the strategy faces

The specific commercial risk in Mubi’s expansion is the risk that further acquisitions do not replicate The Substance’s commercial performance. The specific economic structure of the company depends on the specifically-rare title-level breakout producing substantial-enough returns to compensate for the substantially-lower returns on most acquisitions.

The Substance’s commercial arc is, in structural terms, specifically unusual. The combination of festival prestige (Cannes Best Screenplay), genre categorisation (body horror), specifically-recognisable lead performance (Demi Moore), and specifically-effective marketing campaign produced a commercial performance that exceeded both critical and commercial expectations. The specifically-comparable 2025 title Mubi has acquired that might generate comparable returns has not yet been identified.

What to watch

Three things across 2025 and 2026. First, the 2025 Mubi theatrical slate performance in aggregate. Whether the average-title performance across the expanded slate produces the expected financial results, or whether specifically-below-average performance pressures the company’s financials. Second, any further financing rounds. Mubi’s current business model requires continued capital injection to fund the specifically-expanded acquisition pace. Third, the specific strategic question of whether Mubi enters the US theatrical distribution market at greater scale. The company’s specific North American theatrical distribution has been more limited than its European presence, and the US market represents the single largest expansion opportunity.

The Substance was a specifically-effective proof of concept. What Mubi does next depends on whether the proof of concept extends to the next acquisition, and the one after that.